EUROPEAN CHAMBER FIFTH MEDICAL DEVICE FORUM 中国欧盟商会第五届医疗器械论坛 Go back »
Click here to view pictures of this event.
-
Time2024-09-06 | 09:00 - 16:30
-
Venue:Infinity Ballroom, Hilton Beijing
-
Address:Infinity Ballroom,1F, 1 Dong Fang Road, North Dong Sanhuan Chaoyang, Beijing
北京市朝阳区东三环北路东方路一号希尔顿酒店一层天元宫 -
Fee:Members: 1280 |
Non Members: 1580
The European Union Chamber of Commerce in China and the European Coordination Committee of the Radiological, Electromedical and Healthcare Information Technology Industry (COCIR) will jointly host the 5th Medical Devices Forum on 6th September 2024 in Beijing.
随着全产业链要素的逐步开放与创新，医疗器械行业的发展迎来了前所未有的新机遇。为了进一步推动行业的创新与进步，中国欧盟商会携手欧洲医用影像、电子医学与卫生信息技术行业协会(COCIR)，决定于二〇二四年九月六日，在北京隆重举办第五届医疗器械论坛。
As globalisation and technological advancement continue to evolve, open innovation along the entire industrial chain is pivotal for promoting the development of the medical device industry. The forum intends to explore how best to promote innovative productivity in the industry— through integration and innovation—to fulfil the demands of modern healthcare systems.
本次论坛的主题为“全产业链要素开放创新，构建医疗器械行业新质生产力”。在当前经济全球化和科技快速发展的背景下，全产业链的开放与创新成为了推动医疗器械行业高质量发展的关键。我们希望通过本次论坛，深入探讨如何通过全产业链的整合与创新，构建出医疗器械行业的新质生产力，以适应新时代的需求。
The core topics for discussion will include the innovation and development of the entire industrial chain of medical devices, the regulation and related policies of intelligent medical devices, the transformation of scientific and technological achievements, industrial upgrading, and the construction of new productive forces. The event will feature experts from government agencies, medical institutions, universities and industry as keynote speakers for promoting diversified communication.
鉴此，论坛将围绕医疗器械全产业链的创新与发展、智能医疗器械的监管与政策、科技成果转化与产业升级、以及新质生产力的构建等核心议题展开深入讨论，邀请政府机构、医疗机构、学术团体、医疗健康产业等多领域专家出席，促进多元化的沟通交流。
Open Innovation throughout the Industrial Chain, Increasing Productivity in the Medical Device Industry
主题：全产业链要素开放创新，构建医疗器械行业新质生产力
Language: English/Chinese
语言：英文/中文（大会设中英文同声传译） *Simultaneous interpretation will be provided.
Agenda 会议日程
Host of the Event: Ms. Jessica Yuan, Head of Industry Desks, European Union Chamber of Commerce in China 袁洁 中国欧盟商会行业事务负责人
08:00-09:00 Registration/Check-In 注册/签到
09:00-09:05 Welcome Remarks 欢迎辞
- Mr. Jens Eskelund, President, European Union Chamber of Commerce in China
彦辞 主席，中国欧盟商会
09:05-09:10 Opening Remarks 开幕辞
- Mr. Klaus Zenkel, Vice President, European Union Chamber of Commerce in China
高志豪 副主席，中国欧盟商会
Main Forum 主论坛
09:10-09:35 Keynote: Review and Prospect of Medical Device Regulatory Updates in China 主题演讲：中国医疗器械法规更新的回顾与展望
- Mr. Minhao Tang, President, Shanghai Association of Food and Drug Safety
唐民皓 会长，上海市食品药品安全研究会
09:35-10:00 Keynote: Pharmaceutical Innovation Incentive under the Whole Policy Chain 主题演讲：全政策链条下的医药创新激励
- Prof. Ming Wu, Professor, Health Policy and Management at the School of Public Health, Peking University
吴明 教授， 北京大学公共卫生学院卫生政策与管理系
10:00-10:15 Keynote: Improving Productivity in the Medical Device Industry 主题演讲：提高医疗器械行业新质生产力
- Mr. Huanbo Zhang, Head, Social Affairs Department (Health Department), CCIEE
张焕波 部长，中国国际经济交流中心社会事业部（卫生健康部）
10:15-10:40 Keynote: Technological Innovation Leads High-Quality Industry Development in the Digital and Intelligent Era 主题演讲：以科技创新引领数智时代的产业高质量发展
- Mr. Jiang Yu, Professor/ Executive Director, Institute of Science and Development - Chinese Academy of Sciences
余江 教授、执行主任，中国科学院科技战略咨询研究院产业科技战略研究中心
10:40-11:05 Coffee Break 茶歇
11:05-11:30 Keynote: Approach and Progress of Medical Service Price Reform 主题演讲：医疗服务价格改革思路和进展
- Mr. Changsong Jiang, Associate Researcher, Assistant of Director, National Healthcare Security Research Institute of Capital Medical University
蒋昌松 副研究员，首都医科大学国家医保研究院院长助理
11:30-11:55 Keynote: Green Productivity – Sustainability Impacts on Medical Devices 主题演讲：绿色生产力-可持续发展对医疗器械产业的影响
- Mr. James Vetro, Co-Chair, COCIR Sustainability Committee; Chair, COCIR Eco-design Working Group
James Vetro先生，欧洲医用影像、电子医学与卫生信息技术行业协会（COCIR）可持续发展委员会联合主席，生态设计工作组主席
11:55-14:00 Buffet Lunch自助餐
14:00-15:00 Roundtable I: Sharing of Insights from Industry, Academia and Research on Industry Hotspots 圆桌对话一：行业热点产、学、研洞见分享
- Dr. John Cai, Founder and Executive Chairman, Academy of China Healthcare Innovation Platform
蔡江南 上海创奇健康发展研究院创始人、执行理事长
- Ms. Alice Xu, Vice President, Boston Scientific China
徐萍 副总裁，波士顿科学中国
- Ms. Chie Iwaishi, SVP of Regulatory & Clin Affairs, JAPAC, Edwards Lifesciences
岩石千枝 法规及临床事务资深副总裁，爱德华兹生命科学日本及亚太地区
- Mr. Zhuang Cao, Director, External Affairs and Market Access Department, Johnson & Johnson (China) Medical Ltd.
曹庄 强生医疗科技对外事务与市场准入总监
Moderated by Ms. Annie Yin, Vice President of Medical Regulatory, Roche Diagnostic China
主持人：尹琦曼 医学法规事务副总裁，罗氏诊断中国
15:00-15:20 Coffee Break 茶歇
15:20-16:20 Roundtable II: Strategic Management in Digital Healthcare between China and Europe, and Promoting the Entry of International Innovative Medical Devices into the China-Europe Market 圆桌对话二：数字医疗领域中欧管理重点，及促进国际创新医疗器械进入中欧市场
-
Ms. Ruohan Zhang, Deputy Director of the RWD Transformation Office of the Management Bureau, The Bo’ao Lecheng International Medical Tourism Pilot Zone, Head of Bo’ao Lecheng International Innovation Medical Device Exchange and Trading Center
张若寒 海南博鳌乐城国际医疗旅游先行区管理局 真研转化处副处长，乐城国际创新药械转化交易中心负责人
- Ms. Peipei Lang, Chief Expert of Beijing International Data Exchange
郎佩佩 首席专家，北京国际大数据交易所
- Mr. Björn Nolte, Chair of COCIR Data and Artificial Intelligence Working Group
Björn Nolte 主席，欧洲医用影像、电子医学与卫生信息技术行业协会（COCIR）数据与人工智能工作组
- Mr. Leo Xia, Center of Clinical Excellence Head, Roche Diagnostics
夏磊 资深临床优化总监，罗氏诊断中国
- Mr. Jing Lu, Partner, Shihui Law Firm
卢璟 合伙人，世辉律师事务所
Moderated by Ms. Jessica Yuan, Head of Industry Desks, European Union Chamber of Commerce in China
主持人：袁洁 行业事务负责人，中国欧盟商会
16:20-16:30 Closing Remarks 闭幕辞
- Mr. Adam Dunnett, Secretary General, European Union Chamber of Commerce in China
唐亚东 秘书长，中国欧盟商会
Terms & Conditions
Events have limited seating so to ensure your attendance we encourage advance online registration and payment. We cannot guarantee entry to anyone not registered in advance.
- Members can pay via wechat QR code once registered.
- Non-members will receive an email with a payment code shortly.
Fapiao will be mailed to you within 5-10 working days after the event. The event follows the Chatham House rule unless otherwise stated.
Advisory Council Policy
Advisory Council members will be charged at regular member rate for this event. For further information contact Luyang Syvänen lsyvanen@europeanchamber.com.cn
Cancellation Policy
If you cannot attend the forum, please cancel your registration no later than 18:00 on 3rd September, 2024(Tuesday). The Secretariat will refund the fees within 10 working days after the forum. If you fail to notify us of your cancellation before the deadline, you will be charged for event costs.
To cancel you can: 1) email cdu@europeanchamber.com.cn, or 2) cancel online if you registered for the event through the website.
Disclaimer
Please notice that European Union Chamber of Commerce in China might take photographs from the event and post these on its public web-page (or social media platforms) in order to create awareness of these events. By attending this event you consent to European Union Chamber of Commerce in China taking and using such photographs as described above.
Speakers
Mr. Jens Eskelund
Jens Eskelund was born in 1970 in Aarhus, Denmark. He holds an MA in philosophy and has studied at University of Aarhus and University of Texas at Austin. He has also pursued studies in Chinese at Renmin University in Beijing. Coming to Beijing as a student in 1998, Jens Eskelund began his career in China as Commercial Officer at the Danish Embassy to China before taking on a position in marketing for Maersk Line in Beijing in 2000. He has since held positions as General Manager for Public Affairs for Maersk Line in China and later Director of Public Affairs for North Asia before assuming his present role as Chief Representative for Maersk in the Greater China Area and North-East Asia. Primary focus areas comprise engaging government entities, institutions and trade associations on matters of policy, regulatory environment and business development on behalf of the companies within the Maersk Group.
Jens Eskelund is a former Chairman of the Danish Chamber of Commerce in China as well as the Vice President and Chair of Maritime Working Group of the European Chamber. Jens was elected as the President of European Chamber in May 2023.
彦辞先生于1970年出生于丹麦奥胡斯，曾就读于奥胡斯大学和德克萨斯大学奥斯丁分校，拥有哲学硕士学位。1998年，他来到中国人民大学攻读汉语，随后担任丹麦驻华大使馆商务专员，并于2000年加入马士基航运公司担任市场营销岗位，此后分别担任马士基航运公司在华公共事务总经理，以及北亚区公共事务总监。现任马士基集团大中华区及东北亚区首席代表，主要工作包括代表马士基集团旗下公司与政府机关、机构和贸易协会就政策、监管环境及商业发展等事务进行沟通。彦辞先生曾任中国丹麦商会主席，以及中国欧盟商会的副主席及海事工作组主席。2023年5月，彦辞先生被选为中国欧盟商会主席。
Mr. Klaus Zenkel
Born in Germany and graduated in Industrial Engineering. Until late 80's mainly remained in Germany near his hometown in Erlangen, where he had a position at Siemens Healthcare HQ.
From 1993 to 2006 he was based in Hongkong, Malaysia, Germany and China for several executive management positions within the Siemens Healthcare organization, one of which was Technical Director at Siemens Healthineers facility (SSMR), based in Shenzhen's Hi-Tech Industrial Park.
In 2006 start-up and developed from scratch the Shenzhen subsidiary of a Swiss Company, Imedco AG. Imedco is global player involved in the healthcare Industry, manufacturing MRI shielding solutions for hospitals and research institutions.
Involvement at European Chamber South China Chapter board since 2016. As an active board member of the European Chamber South China Chapter he holds the Chair of the board position since 2021. In the capacity as EU Chamber Vice President supports the member companies and meets with government officials on a regular basis to discuss the current economic and technological issues.
In March 2021 Klaus was elected as a Director of the Board at the Swiss Chamber in South China. He is also a member of the German Chamber in South China.
高志豪先生出生于德国埃朗根市，毕业于工业工程专业，曾于埃朗根市附近的西门子医疗就职至1980年代末。1993年至2006年，他在中国香港、马来西亚、德国和中国大陆担任西门子医疗的多个高层管理职位，包括位于深圳高新技术产业园区的西门子医疗（SSMR）技术总监。
2006年，高先生成立了瑞士公司益迈得可科技（Imedco AG）在深圳的子公司。益迈得可是全球医疗行业的重要参与者，为医院和研究机构提供核磁共振屏蔽方案。
2016年起，高先生加入中国欧盟商会华南分会，作为华南分会的董事会成员，并于2021年起担任董事会主席。他同时担任中国欧盟商会副主席，支持会员公司，并定期与政府官员会面，讨论当前的经济和技术问题。2021年3月，高先生当选为中国瑞士商会华南分会的董事会成员。他同时也是中国德国商会华南分会的成员。
Mr. Minhao Tang
Mr. Tang Minhao currently serves as the President of the Shanghai Association of Food and Drug Safety, and holds positions as a Legislative Consultant for the Shanghai Municipal People's Government and as a Legal Consultant for the Shanghai Municipal Food and Drug Administration. He is also a researcher at the Research Center for National Drug Policy and Ecosystem (NDPE) at China Pharmaceutical University, along with serving as a Supervisor and Specialist at CHIP Academy Innovation. His expertise is further recognized by his role as an Arbitrator with the China International Economic and Trade Arbitration Commission.
Previously, Mr. Tang held significant leadership roles, including Deputy Director of the Shanghai Municipal Food and Drug Administration. He was also the Deputy President of the China Health Law Society.
唐民皓先生目前担任上海市食品药品安全研究会会长；上海市人民政府立法咨询专家；上海市药品监督管理局法律顾问；中国药科大学 NDPE研究员；上海创奇健康发展研究院监事、专家；中国国际经济贸易仲裁委员会仲裁员。
此前，唐民皓先生曾担任上海市食品药品监督管理局副局长及中国卫生法学会副会长。
Prof. Ming Wu
Professor and Doctoral Supervisor, the Department of Health Policy and Management, School of Public Health, Peking University; Director, Center for Health Policy and Technology Assessment; Chairman, the Medical Insurance Professional Committee of the Chinese Health Economics Association; Vice President, the Medical Care Industry Committee of the China-Asia Economic Development Association.
Prof. Wu’s research focus on health economics, health policy and health politics. As a project leader, she has directed over 100 research initiatives funded by various central government bodies, including the Medical Reform Office of the State Council, the National Health Commission, and the National Healthcare Security Administration, as well as local health departments and significant national social science projects. Prof. Wu conducts policy research and evaluation on topics such as the coordinated development and governance of medical treatment, medical insurance and medicine supply, public hospital reform, DRG/DIP payment reform, procurement policies of pharmaceutical products and medical consumables, medical service pricing, supervision of health insurance fund, National Basic Public Health Services Programs, hierarchical medical system and medical treatment partnership system.
北京大学公共卫生学院卫生政策与管理系教授、博士生导师；北京大学医学部卫生政策与技术评估中心主任。兼任中国卫生经济学会医疗保险专业委员会主任委员、中国亚洲经济发展协会医养结合产业委员会副会长。
主要研究方向为卫生经济、卫生政策、卫生政治。作为课题负责人主持研究了来自国务院医改办、国家卫健委、医保局等中央政府部门、地方卫健委、医保局以及国社科重大项目等100余项，包括“三医”协同发展与治理、公立医院改革、DRG/DIP改革、药品和耗材集采政策、医疗服务价格政策、医保基金使用监管、基本公共卫生项目、分级诊疗、医联体建设等政策研究/评估。
Mr. Huanbo Zhang
Zhang Huanbo is the head of Social Affairs Department (Health Department), CCIEE, standing director of China Health Economics Association Healthcare Reform Branch, Editor in Chief of the Evaluation on Hygiene and Health Development Blue Book in China. In recent years, he has mainly engaged in research on biopharmaceutical industry policies and healthcare reform policies. He has published 4 monographs and co-authored more than 10 books. He has published nearly 100 journal articles and finished more than 100 Internal references, dozens of which have received important instructions from national leaders. He has also hosted many projects from the National Natural Science Foundation of China, the National Health Commission, the National Development and Reform Commission, the Ministry of Commerce, and others.
张焕波，中国国际经济交流中心社会事业部（卫生健康部）部长，中国卫生经济学会医改分会常务理事，《卫生健康发展蓝皮书》主编，近年来主要从事生物医药产业政策、医改政策研究，出版专著4部，合著10余部，学术文章近百篇，内参100余篇，数十篇获得国家领导人重要批示。主持国家自然科学基金委、卫健委、发改委、商务部等课题若干。
Mr. James Vetro
James leads advocacy efforts with government regulators within industry trade associations and standards development organizations. He chairs DITTA’s Environmental Policy Focus Group, an international trade association for diagnostic imaging manufacturers. He also chairs the eco-design “self-regulatory initiative” (SRI) committee within COCIR, a medical device industry group in Europe and is the deputy-chair for COCIR’s Environmental committee. He is a co-chair of the AdvaMed Environmental committee that promotes industry policies on environmental regulations in the US.
James is also the co-chair of AAMI’s Sustainability Committee. He is a member of the IEC TC111 USNC and IPC Standards development organizations associated with technical and environmental standards.
James holds BSEE and MSEE degrees in electrical engineering. He joined GE HealthCare in 1984 designing electronics for the newly formed MRI product line. He progressed through several management roles in MRI Engineering until moving into his current organization in 2006 where he leads the Product Compliance Engineering organization.
James在各行业贸易协会和标准制定组织中承担对政府监管机构的宣传工作，担任全球诊断影像、医疗IT和放射治疗行业协会（DITTA）环境政策工作组组长，欧洲医用影像、电子医学与卫生信息技术行业协会（COCIR）内部的生态设计“自我监管倡议”委员会主席，以及COCIR环境委员会的副主席。他同时担任美国先进医疗技术协会（AdvaMed）环境委员会联合主席，该委员会旨在在美国推动环境法规相关的行业政策。
James同时担任美国医疗仪器促进协会（AAMI）可持续发展委员会的共同主席，并且是与技术和环境标准相关的国际电工委员会（IEC）电工电子产品与系统的环境标准化技术美国国家委员会（USNC）及国际电子工业联接协会（IPA）标准制定组织的成员。
James持有电气工程学士与硕士学位，于1984年加入通用电气医疗系统公司，负责新成立的核磁共振成像（MRI）产品线的电子器件设计。他曾在MRI工程领域担任多个管理职位，于2006年进入目前所在部门，领导产品合规工程团队。
Prof. Jiang Yu
Prof. Jiang Yu is the Professor of Institutes of Sciences and Development, Chinese Academy of Sciences. He is also the Full Professor in School of Policy and Management, University of Chinese Academy of Sciences(UCAS). Prof. Yu is also the Director of Research Center of Network Innovation and Development, UCAS.
余江教授是中国科学院科技战略咨询研究院产业科技战略研究中心，中国科学院大学教授和博士生导师，他担任过剑桥大学英国皇家学会研究员（Royal Society International Fellow）。余江研究员现担任中国科学院大学网络创新与发展研究中心执行主任，中国科学院交叉科学研究中心副主任。
余江研究员长期从事全球化背景下的高技术产业发展与战略、数字化与信息技术创新政策等研究。他曾经受邀担任“2015年中欧高层创新对话”、“2016 ,2017和2018年中德创新对话”中方核心专家组成员。
Mr. Changsong Jiang
Mr. Jiang Changsong is an Associate Researcher and Assistant of the Director at the National Healthcare Security Research Institute of Capital Medical University. He specializes in healthcare security and health economics research, having been awarded the First Class Prize for Outstanding Research Achievements by the National Healthcare Security Administration. Additionally, he serves as a member of the Expert Group on Pharmaceutical Pricing and Tendering Procurement, a committee member of the Healthcare Security Standardization Working Group, an Executive Council Member of the China Health Insurance Research Association, and a Standing Committee Member of the Special Committee on Pharmaceutical Policy of the China Health Economics Association.
蒋昌松，副研究员，首都医科大学国家医保研究院院长助理，主要从事医疗保障和卫生经济研究工作，曾获国家医保局优秀课题研究成果一等奖。兼任医药价格和招标采购专家组成员、医疗保障标准化工作组委员、中国医疗保险研究会常务理事、中国卫生经济学会药物政策专委会常委。
Dr. John Cai
John Cai is the Founder and Executive Chairman of Academy of China Healthcare Innovation Platform (CHIP Academy), a non-for-profit healthcare think-tank. He was the ex-Director of Centre for Health Care Management and Policy at China Europe International Business School (CEIBS). For near 30 years, he has been involved in teaching, research and consulting at universities of both China and U.S., consulting company and the US government in the field of health economics, management and policy. He received Ph.D. in Public Policy from Brandeis University in US, and MA in Economics at Fudan University in China.
Dr. Cai participated in the design, implement and evaluation of the first comprehensive Health Care Reform Plan (Massachusetts) in the U.S. and working actively in the design of the latest China’s National Health Care Reform Plan. In China. Dr. Cai was the Co-Founder and Director of the Institute of Economic Development at East China University of Science and Technology and the first Chair at Department of Public Economics of Fudan University.
Dr. Cai received 1990 Sun Ye-fang National Economic Science Prizes-Best Paper Award (China’s top economic award), 2002 Most Outstanding Abstract Award by Academy for Health Services research and Health Policy Annual Research Meeting in Washington D.C.
蔡江南教授是上海创奇健康发展研究院创始人和执行理事长。他在中国和美国的大学、咨询公司、和政府部门从事了三十年的卫生经济和卫生政策的教学、研究和咨询工作，发表了大量有影响的研究成果。参与了美国第一个（麻省）全民医疗保障制度改革方案的设计、实施和评价，以及中国新医改方案的研究工作。
他出版了《医疗卫生体制改革国际经验》、《寻路医改：中国卫生政策的创新与实践》、《中国医健政策的思考与探索》、《中国健康产业创新蓝皮书》。创立了 “卫生政策上海圆桌会议”、“中国健康产业创新平台（CHIP或奇璞奖），在医疗健康行业产生了很大影响。他担任过独立董事的企业包括迪安诊断、上药集团、药明康德、贝达药业、诺维赞生物科技等。
蔡教授曾担任中欧卫生管理与政策中心主任、华东理工大学经济发展研究所（所长）和商学院的主要创始人之一、复旦大学经济学院公共经济系第一任系主任。曾获1990年孙冶方经济科学论文奖（我国经济学最高奖）、2002年美国卫生研究学会最杰出文摘奖。他于1997年获得美国布兰戴斯大学社会政策博士、1984年复旦大学经济学硕士、1982年华东师范大学经济学学士。
Ms. Ping Xu
Vice President of China at Boston Scientific and is responsible for Healthcare Economic and Government Affairs, PR & Communications and Business Innovation & Solutions.
Besides, she successively serves as co-chairperson for medical and health programs of American Chamber of Commerce in China, chairperson of Medical Supplies Consultative Committee of European Union Chamber of Commerce in China as well as executive director in Chinese Hospital Association and China Health Economics Association. Alice Xu graduated from Southeast University majoring at Preventive Medicine and obtained EMBA degree from Cheung Kong Graduate School of Business.
现任波士顿科学中国区政府事务、公共关系及业务创新与解决方案部副总裁。
她毕业于东南大学预防医学，并获得长江商学院EMBA 管理学位，先后担任中国美国商会医疗卫生合作项目联合主席、中国欧盟商会医用耗材咨询委员会主席、中国医院协会常务理事、中国卫生经济学会常务理事等职务。
Ms. Chie Iwaishi
Chie Iwaishi, Edwards Lifesciences, Regulatory and Clinical Affairs, responsible for Japan, Asia, and the Pacific. She joined Edwards in 2018, with extensive leadership experience in major medical device and pharmaceutical companies.
Prior to joining Edwards, she spent 13 years with Johnson and Johnson, where she held various roles of increasing responsibility in Regulatory Affairs and Quality Compliance functions. Amongst these roles, she was the head of Worldwide Regulatory Affairs for the Cordis franchise, and worked closely with the FDA and global regulators. Chie also held regulatory and clinical leadership roles at Abbott Vascular and Diagnostics and Otsuka Pharmaceuticals. She has presented in a number of academic and regulatory conferences, including TCT, CRT, CVIT, RAPS annual conferences.
Chie holds a Ph.D. in Biomedical Sciences from Tokyo Women’s Medical University-Waseda University Joint Institution, Japan.
岩石千枝， 爱德华兹生命科学，法规及临床事务副总裁。负责日本及亚太地区的业务。2018年加入爱德华兹生命科学公司在大型医疗器械和制药公司有着丰富的领导经验。
加入爱德华兹生命科学以前，她曾在强生公司工作了13年，在法规事务部和质量，合规职能部门的各类岗位承担日益增加的职务。在这些任职岗位中，她曾作为Cordis特许经营的全球法规事务部负责人，与美国食品药品监督管理局（FDA）以及全球监管机构进行过密切合作。岩石千枝女士也曾在雅培心血管健康及诊断和大冢制药担任法规和临床领导。曾在多个学术和监管会议上发表演讲，包括美国经导管心血管治疗学术会议（TCT）、美国心血管研究技术大会（CRT）、日本复杂心血管治疗学大会（CVIT）、美国医疗法规事务学会（RAPS）年会。
岩石千枝女士在日本东京女子医科大学-早稻田大学联合研究所获得了生物医学博士学位。
Mr. Zhuang Cao
Director of External Affairs and Market Access at Johnson & Johnson (China) Medical Ltd.. He has years of experience in social insurance administration and research,and was the director of the Medical Management Office at the National Healthcare Security Research Institute of Capital Medical University.
强生医疗科技对外事务与市场准入总监。具有多年社会保险领域政府管理和研究经验，曾任首都医科大学国家医疗保障研究院医药管理室主任。
Ms. Annie Yin
Ms. Annie Yin currently holds the position of Medical Regulatory Vice President, Roche Diagnostic (China).
She had been working in Regulatory, Clinical and Quality fields in pharmaceutical, medical device and in vitro diagnostic sectors for over 25 years with Eli Lilly, Roche Pharma R&D Center, Sanofi, Beckman Coulter, Medtronic and Johnson &Johnson(Medical).
Before corporate career, Annie served as a pharmacist in hospital for about 3 years. Annie is an active member of professional societies, including EUCCC HCE Working Group, AdvaMed, GHWP,CSDR (China Society for Drug Regulation), CAMDl (China Association of Medical Device industry), Shanghai BME Association, etc.
尹琦曼女士现就职于罗氏诊断(中国)，担任罗氏诊断中国医学法规事务副总裁。
尹女士拥有超过 25 年的药品、医疗器械和体外诊断的注册、临床以及质量管理经验，先后任职于礼来、罗氏制药研发中心、赛诺菲、贝克曼库尔特、美敦力和强生医疗。
在企业就职之前尹女士曾就职于医院药剂科约3年，任药库主管。尹女士活跃于多个专业组织，例如中国欧盟商会医疗器械工作组，先进医疗技术协会 （AdvaMed），全球医疗器械法规协调会（GHWP），中国药品研究会，中国医疗器械行业协会，上海生物医学工程学会等。
Ms. Ruohan Zhang
Ms. Ruohan Zhang, Deputy Director of the RWD Transformation Office of Hainan Bo’ao Lecheng International Medical Tourism Pilot Zone Administration, The Bo’ao Lecheng International Medical Tourism Pilot Zone, Head of Bo’ao Lecheng International Innovation Medical Device Exchange and Trading Center
Ms. Ruohan Zhang holds a Master of Business Administration and has enriched experience in auditing publicly listed companies and managing risk in private equity fund investments. She joined the Hainan Bo’ao Lecheng International Medical Tourism Pilot Zone Administration in 2019, where she is responsible for the introduction and cooperation of innovative pharmaceuticals and medical devices from overseas markets, as well as the RWD policy research and advocacy, and conversion trading platform for innovative medical products.
张若寒，海南博鳌乐城国际医疗旅游先行区管理局 真研转化处副处长，乐城国际创新药械转化交易中心负责人。
工商管理学硕士，拥有多年上市公司审计、私募股权基金投资风控工作经验。2019年入职乐城管理局，负责海外创新药械招商引进合作，乐城真研政策研究与推动，乐城创新药械转化交易平台等工作。
Ms. Peipei Lang
Ms. Peipei Lang is one of the earliest industry experts in China in the fields of data trading, data circulation, and government data operation. As the main person in charge, she has been instrumental in establishing the Beijing International Big Data Exchange. She prompts the construction of the country's first data asset registration center under the Exchange, as well as facilitating the implementation of the country's first pilot projects for data asset evaluation. She has also been involved in the establishment of the Cross-Border Data Service Center of Beijing CBD, successfully completing the first case of cross-border data exchange using standard contracts in the country. She has led the establishment of several municipal government platforms for managing government data operations and has supported the planning and design of data trading centers for various local governments in Hebei, Fujian, and Anhui. She has been deeply involved in drafting the Implementation Opinions on Further Accelerating the Development of the Digital Economy by Better Utilising the Role of Data Elements and the creation plan for the Beijing Data Infrastructure Pilot Zone. She drafts the Beijing Data Trading Service Guide, the Beijing Data Asset Registration Guidelines, and the Implementation Plan for the Beijing Data Circulation and Security Governance Regulatory Sandbox. Additionally, she participated in the formulation of the Measures of Beijing Municipality for the Administration of the Registration of Intellectual Property in Data and the Guidelines of Beijing Municipality for Enterprise Data Intellectual Property (Trial).
She has also contributed to the drafting of the national standard GB/T 38667-2020 " Information technology—Big data—Guide for data classification" and the local standard DB11_T 1918-2021 "Specifications for Classification and Security Protection of Government Data in Beijing." As a lead contributor, she has completed several national benchmark projects, including the Ministry of Agriculture's National Apple Big Data Public Platform, key projects under "Transaction Technology for Scientific Achievements and Data Resource Property Rights,” and the National Pig Big Data Application Resource Platform. She has received recognition as a pilot and demonstration project from the Ministry of Industry and Information Technology in 2018, 2019, and 2022 for her contributions to the development of the big data industry.
She participated in writing the book "From Land Finance to Data Finance." She is a member of the Beijing Digital Economy Standardization Committee, leading the establishment of the Data Trading Working Group within the Beijing Digital Economy Standards Committee. As the lead researcher for a sub-project, she contributed to the study on "The Mechanism for Confirming Ownership and Authorization of Data Elements in centrally-administered state-owned enterprises, Patterns for Rights Protection, Property Rights System, and Market System Research.”
国内最早在数据交易、数据流通、政务数据运营领域的行业专家。作为主要负责人筹备组建了北京国际大数据交易所；推动国内首个数据资产登记中心-北数所数据资产登记中心的建设，推动国内首批数据资产评估试点工作落地；推动建设北京CBD数据跨境流通服务中心，完成了国内首个以标准合同方式实现数据跨境的案例落地。牵头组建设立多个地方政府政务数据运营平台公司，支持国内河北、福建、安徽多地政府数据交易中心的规划设计。深度参与北京数据二十条; 北京数据基础制度先行区创建方案的编写；编写了北京数据交易服务指南；北京数据资产登记指引；北京市数据流通与安全治理监管沙盒实施方案；参与了北京市数据知识产权登记管理办法、北京市企业数据知识产权工作指引（试行）等编制；
曾参与起草了相关大数据国家标准GB/T 38667-2020 《信息技术 大数据 数据分类指南》和地方标准DB11_T 1918-2021 《北京市政务数据分级与安全保护规范》的编制；作为牵头人完成了国家农业部国家苹果大数据公共平台、重点研发计划“科技成果与数据资源产权交易技术”重点专项、国家生猪大数据应用资源平台等多个国家级标杆项目建设落地，先后获得2018年度、2019年度、2022年度工信部大数据产业发展试点示范项目。
参与编写了《从土地财政到数据财政》一书；北京数字经济标准化委员会委员，牵头组建北京数字经济标准委员会数据交易工作组。作为子课题牵头人，参与《中央企业数据要素确权授权机制、权益保护模式及产权制度和市场体系研究》课题。
Mr. Björn Nolte
Mr. Björn Nolte is the Chair of the COCIR Data and Artificial Intelligence Working Group and the Chair of the Base Standard Group of DICOM (Digital Imaging and Communication in Medicine). He manages Innovations, Intellectual Property, and Medical Standards at Siemens Healthineers and brings over 30 years of experience in research and development and innovation across the medical, telecommunication, and air traffic control industries.
Björn Nolte先生是欧洲医用影像、电子医学与卫生信息技术行业协会（COCIR）数据与人工智能工作组主席、医学数字成像和通信（DICOM）基础标准组主席，在西门子医疗负责创新、知识产权和医疗标准工作，在医疗、通信和空中交通管制行业拥有30余年的研发和创新经验。
Mr. Leo Xia
Leo Xia, Center of Clinical Excellence Head, Roche Diagnostics. Responsible for pre-marketing clinical trials in China, EU and US. Collaborated with regulatory bodies and clinical experts to draft the metrics for evaluating clinical performance of breakthrough products. Had experience in cross-border projects and making strategies for global product launch.
夏磊，罗氏诊断资深临床优化总监。曾负责美国，欧洲和中国的上市前临床，并和相关监管机构，临床专家合作制定创新产品的临床评价指标。曾负责跨国项目管理，产品全球商业策略。
Mr. Jing Lu
Jing Lu has an abundance of practical legal experience in the life sciences industry, and has been practicing for more than 15 years. He has advised clients on various license-in/out transactions, CSO deals, broad market programs, retail channel collaboration projects, patient assistance and digital platform management programs, including representing clients in commercial negotiations, due diligence investigations, contract drafting, and legal/compliance risk assessments.
Mr. Lu also specializes in data compliance and anti-bribery, advising clients on setting up and assessing the effectiveness of compliance programs, conducting compliance due diligence for M&A deals, and conducting internal investigations on employees.
Also, Mr. Lu has been recognized by: Chambers & Partners as a 'Leading Individual' in Healthcare in 2023; Legal 500 Asia Pacific as a 'Special Recommended Lawyer' listed in the 'Data Protection' and 'Life Sciences and Healthcare' categories in 2023; and LEGALBAND in the categories of 'Top Ranked Lawyers - Life Sciences and Healthcare' in 2023, and 'China Lawyers of the Year' 2022 (Special recommendation top 15 - Healthcare & Medicine). He holds LL.B.& Bachelor of Economics from Peking University and Columbia University LL.M.
卢璟律师在生命科学领域有着丰富的法律服务经验，执业已超过15年。卢律师为客户提供的服务包括：在各类交易或合作项目中（例如：License-in/out交易、CSO交易、广阔市场项目、零售渠道合作项目、患者援助项目、数字化平台管理项目等）为企业提供商业谈判、尽职调查、协议起草以及法律及合规风险分析等服务。另外，卢律师还专注于数据合规及反腐败合规领域，曾为多家企业搭建合规体系，评估合规治理有效性，在并购交易中开展合规尽职调查，代表企业开展针对员工的内部合规调查等。
卢律师入选Chambers大中华区指南2023年度医疗健康行业领先律师；被The Legal 500亚太地区榜单评为2023年度数据保护领域以及医疗健康与生命科学行业重点推荐律师；入选LEGALBAND 2023年度医疗与生命科学行业中国顶级律师排行榜，并被LEGALBAND评为2022年度医疗健康与医药行业中国律师特别推荐榜15强。他持有美国哥伦比亚大学法学院法学硕士和北京大学法学院法学学士、北京大学国家发展研究院 经济学学士（双学位）。
Mr. Adam Dunnett
Adam’s career has focused on trade & investment advocacy, promotion and association management. As the European Chamber’s secretary general, he is responsible for the overall implementation of its objectives, visibility, membership and advocacy activities across its 7 chapters and 9 offices in China (Beijing, Chengdu, Chongqing, Guangzhou, Nanjing, Shanghai, Shenzhen, Shenyang and Tianjin).
唐亚东（Adam Dunnett）先生的职业生涯主要集中在贸易和投资倡导、推广和协会管理方面。作为中国欧盟商会现任秘书长，他负责制定及执行全国7个分会，9个办公室（北京，成都，重庆，广州，南京，上海，深圳，沈阳及天津）的战略目标、市场推广、会员管理及政府沟通事项。
Ms. Jessica Yuan
Jessica Yuan, Head of Industry Desks at the European Chamber, COCIR China Representative (European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry, shortened to "COCIR").
At the European Chamber, Jessica takes upon COCIR China activities, medical device industry affairs and other related responsibilities. She has gained 12 years of experience in the field of regulatory affairs in medical devices and pharmaceutical manufacturing enterprises. Previous to her RA career, Jessica had worked in ICU of Peking Union Medical College Hospital after graduating from PUMC.
袁洁，中国欧盟商会行业事务负责人，欧洲医用影像、电子医学与卫生信息技术行业协会（COCIR）中国代表。
主要负责COCIR中国事务、中国欧盟商会医疗器械等行业的支持。曾任职于医疗器械以及药品制造企业12年，负责法规事务部。在此之前于中国医学科学院北京协和医院ICU工作。毕业于中国协和医科大学。